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Main Elements of the Pathomechanism of  
Atrial Remodelling 
Atrial fibrillation (AF), the most common cardiac disorder, rarely 
induces sudden/arrhythmogenic cardiac death; however, considering 
its clinical course it cannot be considered as a benign heart disease at 
all. The coordinated electromechanical heart function in sinus rhythm 
(SR) is changed to uncoordinated atrial activity in AF characterised by 
extremely high frequencies (400-800/min), rendering the atria unable 
to perform regular muscle contractions. The decreased ventricular 
filling due to the lack of a proper atrial systole and the irregular 
ventricular depolarisations/contractions caused by erratic impulse 
conduction from the atria are responsible for a 10-25% reduction in 
cardiac output. 
 
The functional andumoror structural changes that create a substrate 
for repetitive renewal of the arrhythmia, thus contributing to atrial 
remodelling in AF include: a) functional and morphological injuries of 
atrial myocytes (sarcolemmal ion channels, signalling and functioning 
proteins), cell-surface adhesion molecules and coupling structures 
(gap-junctions), the extracellular matrix, and the endocardial 
endothelium; b) dysfunction of neurohumoral systems, e.g., the 
autonomic nervous system and renin-angiotensin-aldosterone 
system (RAAS). 
 
The most significant electrophysiological changes occurring during AF 
are depicted in Figure 1. In most cases arrhythmia is induced by an 
atrial extrasystole (ES). The reentry activity responsible for AF 
maintaining is based on anatomical and/or functional conductivity 
block(s), the coexistence of at least or more than five to six small or 
large activating wavefronts (multiple wavelets) rotating in the 
inexcitable/refractory heart regions.1,2 
 
Figure 1B is a schematic illustration of pathophysiological changes that 
probably play a role in the induction of AF. Three arrhythmogenic 
factors may cause venoatrial extrasystoles and, consequently AF via:  
1) increased automaticity; 2) reentry; 3) triggered activity as delayed 
afterdepolarisations (DADs) or early afterdepolarisation (EADs). AF is 
initiated when ectopic activity triggers reentry in a vulnerable 
substrate. Instable membrane potentials either at the AP plateau or 
resting level (EADs, DADs) can serve as a trigger for ectopic activity. 
Currently it is largely known that in the pulmonary sleeve veins and in 
some vestigial anatomical structures exist cell types that qualify for 
spontaneous automaticity/pacemaker activity. These can form ectopic 
foci, which could initiate single- or multiple-circuits reentry.2 
 
Electrical, Structural and Contractile Remodelling  
The shape and duration of action potential (APD) are determined by the 
equilibrium between the relative intensity of the inward ionic currents 
(especially by the inward L-type Ca2+ current) and of the outward 
repolarising K+ currents. At the very core of electrical remodelling lies 
the shortening of the atrial effective refractory period (AERP) and APD, 
respectively within minutes after the initiation of AF, rendering a 
triangular shape to the AP (Figure 2). The AERP shortening is due mainly 
to the loss of function (downregulation) of the ICaL together with the 
increase (upregulation) of several K+ current densities and/or 
membrane permeability.3,4 According to our current knowledge, 
the three most likely components responsible for atrial electrical 
remodelling, APD shortening and triangularisation, are as follows: 
1) downregulation of ICa,L; 2) upregulation of IK1; 3) activation of the 
constitutive (ligand independent) IK,ACh. A more detailed description 
about the effect of electrical remodelling on all known important 
cardiac transmembrane currents is provided in several 
comprehensive papers.1,5 
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The frequency of atrial activation becomes extremely high in AF 
(400-600/min) therefore in spite of the shorter APD plateaus, the 
amount of calcium (Ca2+) entering the myocytes significantly increases 
leading to impaired intracellular Ca2+ homeostasis (Ca2+-mishandling).6 
The elevated Ca2+-influx increases the activation of ryanodine receptors 
(Ca2+-release [RyR2]-channel) leading to a higher number of 
arrhythmogenic Ca2+ sparks.7 The cells respond to Ca2+-overload by 
reducing the expression of Ca2+-channels (downregulation), that within 
a relatively short time significantly shortens APD.8 Impaired Ca2+ 
homeostasis also manifests in deterioration of contractile (contractile 
remodelling) and diastolic function of the atria with subsequent wall 
stiffness and increased stretch that with the time will cause left atrial 
dilation. Dilation and geometric deformation of the atria are the most 
important pathomorphological factors determining the propensity for 
AF recurrence (structural remodelling), the key factor responsible for 
the deteriorating nature of AF (paroxysmal  persistent  permanent). 
 
Two types of electrical and contractile remodelling exist: a rapid one, 
which occurs within minutes to hours, and a chronic one that develops 
in days or weeks.9 However, both electrical and contractile remodelling 
is fully reversible after conversion to AF. Conversely, the development 
of structural remodelling is a slower process, but may cause irreversible 
morphological alterations within three to four months. Microfibrosis 
and left atrial dilation are the changes that will hamper the 
pharmacological conversion of AF and/or the maintenance of SR.10,11   
 
Prevention and Therapy of Atrial Remodelling  
Therapeutic Principles and Treatment Options in AF 
Restoration of normal SR (rhythm control) represents the optimal 
therapeutic goal in AF. Whilst rhythm control usually requires a 
combination of pharmacological and non-pharmacological treatments, 
rate control involves other mechanisms including prolongation of 
atrioventricular nodal refractoriness or slowing of AV node conduction. 
The latter can be achieved by several classes of antiarrhythmic drugs, 
including β-blockers, calcium channel blockers or amiodarone.12  
 
Suppression of hyper-excitability of pulmonary veins or atrial tissue 
can terminate AF by eliminating ectopic triggers and hence support 
rhythm control. Classical antiarrhythmic drugs used to reach this goal 
include Na+ channel blockers or multiple ion channel blockers such as 
amiodarone.13 According to the leading wavelet concept,1,14 short 
refractoriness and slow conduction will increase the likelihood of 
reentry. Theoretically, the reentry circuits can be interrupted when 
conduction is enhanced and refractoriness prolonged so that the 
reentrant wavefront will reach tissue that is still in refractory state. 
Available antiarrhythmic drugs can prolong refractoriness but will slow 
instead of enhancing conduction via blocking the Na+ channels.  
 
Novel Pharmacological Drugs/Compounds for the 
Treatment of AF 
Currently available antiarrhythmic drugs for the treatment of AF are far 
from being ideal, and impose serious concerns regarding efficacy and 
safety. An ideal drug against AF should suppress atrial triggers and 
disrupt atrial reentry circuits by prolonging atrial refractoriness and 
slowing intra-atrial conduction. Its atrial selectivity should minimise the 
ventricular proarrhythmic effects and be safe in patients with 
concomitant cardiovascular disease, in particular coronary artery 
disease and heart failure. This is called the atrial selective drug concept. 
Novel compounds can block specific or multiple ion channels, 
preferably in an atrial-selective manner, and they can be directed at 
non-ion channel targets including upstream inflammatory or infiltrative 
processes or they may influence gap-junctions (Figure 3 and Table 1).  
 
Specific and Multiple Ion Channel Blockers 
Numerous class III or repolarisation-delaying compounds have been 
partly developed and then abandoned, largely because of the risk of 
torsades de pointes brought about by their detrimental effects on 
ventricular repolarisation. These drugs are especially specific or multiple 
blockers of the main repolarising potassium currents especially IKr, IKs, 
Ito, IK1, IKATP etc. The main ion channel blocker drugs or investigational 
compounds used/designed for treating AF are as follows: azimilide (IKr 
and IKs blocker),
15,16,17  HMR-1556 (IKs blocker),
18,19 AZD-7009 (IKr and 
INablocker),
20,21,22 dronedarone (amiodarone derivate multichannel 
blocker)23,24,25,26,27 and tedisamil (multichannel blocker).28,29,30,31 
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Figure 1. Panel A. Main factors that induce and maintain AF.  
Panel B. AF is initiated by an extrasystole started from a pacemaker 
region (usual left upper pulmonary vein), created by atrial tachycardia 
remodelling (APD shortening). The electrical perpetuator may be 
a single/mother wave and/or multiple wave/circuit reentry. Atrial 
ischaemia and inflammation are known reentry facilitators. The key 
factors of structural/morphological remodelling are atrial myocardial 
(micro)fibrosis and left atrial dilation. (AF = atrial fibrillation; RA = right 
atrium; LA = left atrium; EAD = early afterdepolarisation; DAD = delayed 
afterdepolarisation; PVs = pulmonary veins; APD = action potential 
duration; RP = refractory period; WL = wavelength). Modified from Ref 
[1] with permission.  control of AF.
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Atrial Selective Ion Channel Blockers 
A novel strategy for development of agents against AF in order to 
avoid ventricular proarrhythmic effects is the development of so-called 
atrial selective drugs. A great deal of effort has been invested into the 
development of atrial specific ion channel blockers to avoid ventricular 
arrhythmogenic effects of currently available drugs. Atrial specific 
targets for AF treatment include the ultra-rapid delayed rectified 
potassium current (IKur), the acetylcholine-regulated inward rectifying 
potassium current (IK,ACh), the constitutively active IK,ACh (CA_IK,ACh i.e., 
which does not require acetylcholine or muscarinic receptors for 
activation), and connexin 40 (Cx40). The channels responsible for IKur 
and IK,ACh are exclusively or nearly exclusively present in atria and 
largely absent in the ventricles. In addition to atrial specific ion 
channels, there are ion channels that are present in both chambers of 
the heart but the inhibition of these channels (especially fast INa) can 
produce predominant electrophysiological changes in atria vs. 
ventricles according to Antzelevitch theory.32 
 
The main atrial selective ion channel blocker drugs or investigational 
compounds used or designed for treating AF are as follows: AVE0118 (IKur 
and Ito blocker),
33,34,35 XEN-D0101 and DPO-1(selective IKur blockers)
36,37,38 
and vernakalant (IKur, INa and INal blocker),
39,40 ranolazine (INa and INaL 
blocker),41,42,43 NIP-142 and NIP-151 (IK,ACh and CA IK,ACh blockers).
44,45 
 
Na+/Ca2+ Exchanger Current Modulators 
The Na+/Ca2+ exchanger current (NCX) exchanges one intracellular Ca2+ 
ion for three extracellular sodium ions. During rapid atrial rates caused by 
AF or pacing, a larger increase in intracellular sodium relative to calcium 
may cause the exchanger to work in the reverse mode, bringing calcium 
into the cell, thus contributing to the shortening of the action potential. 
Since DADs elicited by NCX1 activity61 can trigger AF, block of the 
exchanger has been proposed as a useful antiarrhythmic mechanism. 
However, available blockers of NCX current, KB-R794347 and SEA 040048,49 
possess only poor highly selective inhibiting properties to test whether 
NCX blockade indeed would be ideal drugs for combating AF.  
 
Gap Junction Modulators 
Electrophysiological and structural remodelling of the fibrillating atria 
involves changes in junctions at the atrial intercalated discs. Two major 
isoforms of connexins, Cx40 and Cx43, are specific for the heart.50 There 
are several studies that investigated the function of gap junctions 
during early acute ischaemia, which provided evidence suggesting 
that closing of gap junctions causes conduction velocity slowing.51 
Several peptides such as rotigaptide (GAP-486, ZP123)52,53 and GAP 
13454 have been developed, which by preventing gap junction closing, 
offer a protective effect against AF.  
 
 Non Ion-channel Blockers - Upstream Therapy of AF  
In addition to further developing ion channel based AF therapy, there 
is rapid development of non ion-channel approaches, aimed at 
reducing or reversing structural remodelling, inflammation, and 
oxidative stress injury associated with AF. These are generally referred 
to as upstream therapies.55,56 
 
It has been known for some time that inflammation and oxidative 
injury promote structural remodelling, including interstitial fibrosis, 
fibroblast proliferation, accumulation and/or redistribution of 
collagen, chamber dilation, and hypertrophy. Proarrhythmic actions of 
atrial structural remodelling are generally related to conduction 
disturbances, which promote reentrant arrhythmias. A number of 
experimental and clinical studies have shown that drugs affecting 
structural remodelling, inflammation, and/or oxidative stress such as 
angiotensin-converting enzyme inhibitors, angiotensin II 
receptor blockers, and statins may reduce the occurrence 
of AF,56,57,58 although some studies question the efficacy of 
such therapies in AF.13,59,60,61 Successful development of 
upstream therapy depends on our ability to identify 
factors and signalling pathways involved in the generation 
of atrial structural remodelling, inflammation, and 



































































Figure 2. Transmembrane ionic currents determining atrial action potential 
in sinus rhythm (SR) and in atrial fibrillation (ion channel remodelling). Left 
column depicts ionic current densities, while middle and right columns 
show the changes in the expression of the main current subunit putative 
proteins and genes, respectively. Pictograms present current amplitude and 
























Figure 3. Current prominent investigational strategies for rhythm control of AF.
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Table 1. New drugs and investigational compounds developed for treating AF.
Drugs or investigational 
compounds











Primarily IKr and IKs blocker but 
additionally blocks ICaL and INa 
 (multi-channel blocker)
Several in vitro and in 
vivo animal models
ALIVE, A-STAR, 
A-COMET I and II 
Studies
[15, 16,17]
HMR-1556 Highly selective IKs blocker Several in vitro and in 
vivo animal models
not [18,19]
AZD7009 Primarily IKr and INa blocker, but 
additionally blocks Ito, IKur and IKs 
 (multi-channel blocker)
Several in vitro and in 
vivo animal models





Amiodarone like multichannel 
blocker (INa, ICa, IKr blocker)
Several in vitro and in 
vivo animal models
ADONIS,  ATHENA, 
EURIDIS etc
[23,24,25,26,27]
Tedisamil Multichannel blocker (INa, Ito, IKr, 
IKs, IKATP,  blocker)
Several in vitro and in 
vivo animal models










AVE0118 Primarily IKur, Ito and IK,ACh blocker Several in vitro and in 
vivo animal models
not [33,34,35]
XEN-D0101 Highly selective IKur blocker Several in vitro and in 
vivo animal models
under way [36,37]
DP01 Highly selective IKur blocker Several in vitro and in 
vivo animal models
not [38]
Vernakalant Primarily IKr and INa blocker, but 
additionally blocks Ito, INa, IKr and 
IKs (multichannel blocker)





Primarily INaf and INaL, and IKr 
blocker, but additionally blocks 
ICaL and IKs (multichannel blocker)
Several in vitro and in 
vivo animal models
MERLIN-TIMI 36 [41,42,43]






KB-R7943 Initially developed as selective 
NCX blocker, but additionally 
blocks Ito, IK, IK1, INa, and ICaL
Several in vitro and in 
vivo animal models
not [47]
SEA-0400 Selective NCX blocker, but 
additionally blocks ICaL






Rotigaptide Selective gap junction closer 
peptide
Several in vitro and in 
vivo animal models
not [52,53]
GAP-134 Selective gap junction closer 
peptide
Several in vitro and in 
vivo animal models
not [54]
structural remodelling, inflammation, and oxidative stress in 
development of AF is still not fully understood and varies significantly 
among different AF pathologies. 
 
Conclusions 
Great advances have been made in understanding the mechanisms 
underlying atrial remodelling and avenues of therapy in AF. Ongoing 
research aimed at developing novel pharmacological strategies for the 
management of AF includes both ion channel and non ion-channel 
mediated therapeutic approaches. However, while success to date has 
been modest, the recent identification of atrial- and pathology-
selective targets and compounds able to directly modulate them hold 
promise for the development of effective treatment modalities. New 
antiarrhythmic drugs targeting multiple ion channels or possessing 
high affinity for atrial myocardium are believed to have a more 
favourable risk/benefit ratio than traditional antiarrhythmic drugs. 
Extensive studies utilising a wide range of such agents are currently 
underway with potentially promising results.
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